Methylprednisolone Paten

Methylprednisolone Paten. The method increases purity of the methylprednisolone succinate and reduces content of impurities by crystallization in a specific solvent and in specific conditions thereby increasing security of clinic applications More importantly methylprednisolone sodium succinate lyophilized powder for injection prepared by the methylprednisolone succinate has quality superior to commercially Author 郑伟Publish Year 2011.

The invention discloses a method for preparing methylprednisolone hemisuccinate The method comprises the following step by taking methylprednisolone as a raw material carrying out an esterification reaction between succinic anhydride and methylprednisolone in a reaction solvent in the presence of an alkaline catalyst thereby obtaining methylprednisolone hemisuccinate Author 赵俊志Publish Year 2015.

CN103159817A Preparation method for methylprednisolone

MHRA/CHM advice SoluMedrone® 40 mg (methylprednisolone as sodium succinate) change from lactosecontaining to a lactosefree formulation—risk of serious allergic reactions if formulations are confused (November 2020) With intramuscular use or intravenous use SoluMedrone® 40 mg powder and solvent for solution for injection has been.

METHYLPREDNISOLONE Drug BNF content published by NICE

European Patent Office Prior art keywords methylprednisolone tablet super disintegrant tablets Prior art date 19860401 Legal status (The legal status is an assumption and is not a legal conclusion Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed) Expired Lifetime Application Author Coenraad F Lerk Gerad Klaas BolhuisCited by Publish Year 1987.